Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).

Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).

Abstract: A composition, method and kit comprising a compound for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin and other therapeutic compounds for the control or prevention of diseases states in which ?4?1 is involved.

Abstract: The present invention includes methods of treating allergic skin conditions and disorders by combined administration of an histamine H1 receptor antagonist and a histamine H3 receptor antagonist.

Abstract: Methods of treating chemokine-mediated diseases are disclosed.

Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.

Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.

Abstract: The present invention provides methods of treatment of mental and vascular disorders. In one embodiment, the present invention contemplates the administration of an anti-allergic medication to reduce a patient's symptoms of mental or vascular disorder. The patient may or may not suffer from allergic responses. Likewise, the methods of the present invention may be used to reduce or prevent the symptoms of a mental or vascular disorder. In a preferred embodiment, the anti-allergic medication is a non-sedating or low-sedating antihistamine such as loratadine or desloratadine.

Abstract: The present invention provides methods of treatment of mental and vascular disorders. In one embodiment, the present invention contemplates the administration of an anti-allergic medication to reduce a patient's symptoms of mental or vascular disorder. The patient may or may not suffer from allergic responses. Likewise, the methods of the present invention may be used to reduce or prevent the symptoms of a mental or vascular disorder. In a preferred embodiment, the anti-allergic medication is a non-sedating or low-sedating antihistamine.

Abstract: The present invention provides methods of treatment of mental disorders comprising administering the anti-allergic medication loratadine or a metabolite thereof to reduce a patient's symptoms of a mental disorder.

Abstract: Disclosed are compounds of the formula I wherein:Y represents --CO.sub.2 H, --CO.sub.2 R.sup.6, --C(O)NHR.sup.7, --SO.sub.2 H, --SO.sub.3 H, --SO.sub.3 R.sup.6, --SO.sub.2 NHR.sup.7, --C(O)--N(OH)--R.sup.8, or a group of the formula ##STR1## or a pharmaceutically acceptable addition salt or solvate thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I. Further disclosed is a method for treating or preventing respiratory depression, epileptic seizures or other central nervous system disorders, and for enhancing cognitive performance, by administering an effective amount of a compound of Formula I.

Abstract: Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.

Abstract: A method for treating cough in a mammal comprising administering to said mammal an anti-tussive effective amount of a GABA-B selective agonist such as ##STR1## is described.

Abstract: Forskolin and its disclosed derivatives are useful as antiallergic agents. Certain of the derivatives are novel.

Abstract: A method for producing bronchodilation in a mammal is disclosed. Composition for use in said method are also described.

Abstract: Forskolin and its disclosed derivatives are useful as antiallergic agents. Certain of the derivatives are novel.